公开(公告)号：US20150010475A1

公开(公告)日：2015-01-08

申请号：US14369741

申请日：2012-12-31

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  David S. Peabody ,  Walker Kip Wharton ,  Bryce Chackerian ,  Carlee Erin Ashley ,  Cheryl L. Willman ,  Eric C. Carnes ,  Katherine Epler ,  Robert Eric Castillo

IPC: A61K47/48 ,  C12N15/113 ,  C12N15/11 ,  C07K7/06 ,  A61K31/704

CPC classification number: A61K31/704 ,  A61K47/62 ,  A61K47/64 ,  A61K47/6911 ,  C07K7/06 ,  C12N15/111 ,  C12N15/113

Abstract: The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by CRLF-2 and CD 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing CRLF-2 and CD 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (ALL), including (B-precursor acute lymphoblastic leukemia (B-ALL). Novel CRLF-2 binding peptides and CLRF-2 and CD19-binding viral-like particles (VLPs) useful in the treatment of cancer, including ALL are also provided.

Abstract translation: 本发明涉及其用途，其可用于将可用于递送药物载体的CRLF-2和CD19结合肽进一步修饰的磷脂生物层结合到表达CRLF-2和CD19的细胞中，从而治疗癌症 特别是急性淋巴细胞白血病（ALL），包括（B-前体急性成淋巴细胞白血病（B-ALL）），用于治疗癌症的新型CRLF-2结合肽和CLRF-2和CD19结合病毒样颗粒（VLP） ，也包括ALL。